FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086951200> ?p ?o ?g. }

• W2086951200 endingPage "1738" @default.
• W2086951200 startingPage "1731" @default.
• W2086951200 abstract "Abstract BACKGROUND Lymphocyte‐predominant Hodgkin disease (LPHD) is rare and has a natural history different from that of classic Hodgkin disease. There is little information in the literature regarding the role of chemotherapy in patients with early‐stage LPHD. The objective of this study was to examine recurrence free survival (RFS), overall survival (OS), and patterns of first recurrence in patients with LPHD who were treated with radiotherapy alone or with chemotherapy followed by radiotherapy. METHODS From 1963 to 1996, 48 consecutive patients ages 16–49 years (median, 28 years) with Ann Arbor Stage I ( n = 30 patients) or Stage II ( n = 18 patients), very favorable (VF; n = 5 patients) or favorable (F; n = 43 patients) LPHD, according to the European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte (EORTC‐GELA) criteria, received radiotherapy alone ( n = 37 patients) or received chemotherapy followed by radiotherapy ( n = 11 patients). The percentages of patients with VF disease (11% vs. 9% in the radiotherapy group vs. the chemotherapy plus radiotherapy group, respectively) or F disease (89% vs. 91%, respectively) within the two treatment groups were similar ( P = 1.00). A median of three cycles of chemotherapy with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP) was given initially to six patients and five patients, respectively. A median total radiotherapy dose of 40 grays (Gy) given in daily fractions of 2.0 Gy was delivered to both treatment groups. RESULTS The median follow‐up was 9.3 years, and 98% of patients were observed for ≥ 3.0 years. RFS was similar for patients who were treated with radiotherapy alone and patients who were treated with chemotherapy followed by radiotherapy (10‐year survival rates: 77% and 68%, respectively; P = 0.89). The OS rate also was similar for the two groups (10‐year survival rates: 90% and 100%, respectively; P = 0.43). MOPP or NOVP chemotherapy did not reduce the risk of recurrence outside of the radiotherapy fields. CONCLUSIONS MOPP or NOVP chemotherapy did not improve RFS or OS significantly in patients with VF or F LPHD, although the statistical power was limited. Ongoing clinical trials will help to clarify the role of a watch‐and‐wait strategy or systemic therapy, including anthracycline (epirubicin or doxorubicin), bleomycin, and vinblastine‐based chemotherapy or antibody‐based approaches, in the treatment of these patients. Cancer 2002;94:1731–8. © 2002 American Cancer Society. DOI 10.1002/cncr.10404" @default.
• W2086951200 created "2016-06-24" @default.
• W2086951200 creator A5006742031 @default.
• W2086951200 creator A5017541582 @default.
• W2086951200 creator A5034765756 @default.
• W2086951200 creator A5040275365 @default.
• W2086951200 creator A5059988668 @default.
• W2086951200 creator A5060386553 @default.
• W2086951200 creator A5064158970 @default.
• W2086951200 creator A5066313849 @default.
• W2086951200 creator A5068152076 @default.
• W2086951200 creator A5070451207 @default.
• W2086951200 date "2002-03-15" @default.
• W2086951200 modified "2023-10-16" @default.
• W2086951200 title "European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease" @default.
• W2086951200 cites W1536128075 @default.
• W2086951200 cites W1819862099 @default.
• W2086951200 cites W1890322031 @default.
• W2086951200 cites W1939504905 @default.
• W2086951200 cites W1986294775 @default.
• W2086951200 cites W1994351520 @default.
• W2086951200 cites W2003385864 @default.
• W2086951200 cites W2032975907 @default.
• W2086951200 cites W2038252730 @default.
• W2086951200 cites W2047853141 @default.
• W2086951200 cites W2067571463 @default.
• W2086951200 cites W2077791684 @default.
• W2086951200 cites W2091291718 @default.
• W2086951200 cites W2107202569 @default.
• W2086951200 cites W2120763744 @default.
• W2086951200 cites W2135361829 @default.
• W2086951200 cites W2150373911 @default.
• W2086951200 cites W2166104105 @default.
• W2086951200 cites W2213506447 @default.
• W2086951200 cites W2257019489 @default.
• W2086951200 cites W2263695274 @default.
• W2086951200 cites W2272862175 @default.
• W2086951200 cites W2340481879 @default.
• W2086951200 cites W2370208857 @default.
• W2086951200 doi "https://doi.org/10.1002/cncr.10404" @default.
• W2086951200 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11920535" @default.
• W2086951200 hasPublicationYear "2002" @default.
• W2086951200 type Work @default.
• W2086951200 sameAs 2086951200 @default.
• W2086951200 citedByCount "62" @default.
• W2086951200 countsByYear W20869512002012 @default.
• W2086951200 countsByYear W20869512002013 @default.
• W2086951200 countsByYear W20869512002014 @default.
• W2086951200 countsByYear W20869512002015 @default.
• W2086951200 countsByYear W20869512002016 @default.
• W2086951200 countsByYear W20869512002017 @default.
• W2086951200 countsByYear W20869512002018 @default.
• W2086951200 countsByYear W20869512002019 @default.
• W2086951200 countsByYear W20869512002020 @default.
• W2086951200 countsByYear W20869512002021 @default.
• W2086951200 countsByYear W20869512002022 @default.
• W2086951200 crossrefType "journal-article" @default.
• W2086951200 hasAuthorship W2086951200A5006742031 @default.
• W2086951200 hasAuthorship W2086951200A5017541582 @default.
• W2086951200 hasAuthorship W2086951200A5034765756 @default.
• W2086951200 hasAuthorship W2086951200A5040275365 @default.
• W2086951200 hasAuthorship W2086951200A5059988668 @default.
• W2086951200 hasAuthorship W2086951200A5060386553 @default.
• W2086951200 hasAuthorship W2086951200A5064158970 @default.
• W2086951200 hasAuthorship W2086951200A5066313849 @default.
• W2086951200 hasAuthorship W2086951200A5068152076 @default.
• W2086951200 hasAuthorship W2086951200A5070451207 @default.
• W2086951200 hasBestOaLocation W20869512001 @default.
• W2086951200 hasConcept C121608353 @default.
• W2086951200 hasConcept C126322002 @default.
• W2086951200 hasConcept C141071460 @default.
• W2086951200 hasConcept C143998085 @default.
• W2086951200 hasConcept C146357865 @default.
• W2086951200 hasConcept C151730666 @default.
• W2086951200 hasConcept C2776694085 @default.
• W2086951200 hasConcept C2776755627 @default.
• W2086951200 hasConcept C2777132456 @default.
• W2086951200 hasConcept C2778720950 @default.
• W2086951200 hasConcept C2779112685 @default.
• W2086951200 hasConcept C2779429289 @default.
• W2086951200 hasConcept C2780923524 @default.
• W2086951200 hasConcept C509974204 @default.
• W2086951200 hasConcept C71924100 @default.
• W2086951200 hasConcept C86803240 @default.
• W2086951200 hasConcept C90924648 @default.
• W2086951200 hasConceptScore W2086951200C121608353 @default.
• W2086951200 hasConceptScore W2086951200C126322002 @default.
• W2086951200 hasConceptScore W2086951200C141071460 @default.
• W2086951200 hasConceptScore W2086951200C143998085 @default.
• W2086951200 hasConceptScore W2086951200C146357865 @default.
• W2086951200 hasConceptScore W2086951200C151730666 @default.
• W2086951200 hasConceptScore W2086951200C2776694085 @default.
• W2086951200 hasConceptScore W2086951200C2776755627 @default.
• W2086951200 hasConceptScore W2086951200C2777132456 @default.
• W2086951200 hasConceptScore W2086951200C2778720950 @default.
• W2086951200 hasConceptScore W2086951200C2779112685 @default.
• W2086951200 hasConceptScore W2086951200C2779429289 @default.
• W2086951200 hasConceptScore W2086951200C2780923524 @default.

• next